基于离散选择实验的青光眼效用工具(Glau-U)的开发与验证
本研究在新加坡国家眼科中心青光眼门诊分两阶段开发并验证了偏好-based青光眼效用工具Glau-U,包含6个生活质量属性。304例参与者中,Glau-U效用值随较好眼青光眼严重程度增加而下降,并与视野平均偏差呈中度相关,与EuroQol 5-Dimension效用呈低相关,支持其聚合与区分效度。
要点
- Glau-U包含6个生活质量属性,可用于估算青光眼各严重程度的效用值。
- 较好眼青光眼越重,Glau-U效用值越低,晚期或终末期最低。
- Glau-U效用值与较好眼和较差眼视野平均偏差呈中度相关。
核心结论
- Glau-U效用值在晚期青光眼患者中大幅下降,该工具可能有助于青光眼干预的成本效果分析和资源分配决策。
研究设计与样本
- 第二阶段纳入304名40岁及以上、至少一眼临床诊断青光眼、讲英语或汉语的新加坡公民或永久居民,族裔为华裔、马来裔或印度裔。
主要发现
- 304名参与者平均(SD)年龄68.3(8.7)岁,182名(59.9%)为男性;281名(92.4%)较好眼无视力损害,13名(4.3%)轻度损害,10名(3.3%)中度至重度损害。
- 平均(SD)Glau-U效用值随较好眼青光眼严重程度增加而下降:无0.73(0.21)、轻度0.66(0.21)、中度0.66(0.20)、重度0.60(0.28)、晚期或终末期0.22(0.38),P < .001;与包含前周青光眼健康状态相比,质量调整生命年减少20.7%至76.1%。
- 平均(SD)Glau-U效用值随较好眼视力损害加重而下降:无0.67(0.23)、轻度0.58(0.32)、中度至重度0.46(0.29)。
- Glau-U效用值与较好眼(r = 0.34;P < .001)和较差眼(r = 0.33;P < .001)视野平均偏差呈中度相关,与EuroQol 5-Dimension效用呈低相关(r = 0.22;P < .001),支持聚合与区分效度。
临床怎么用
- Glau-U可用于估算青光眼各严重程度和视力损害状态的效用值,支持成本效果分析。
- 临床中可关注较好眼青光眼严重程度和视力损害对效用值的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A glaucoma-specific instrument for estimating utilities across the spectrum of glaucoma severity is currently lacking, hindering the assessment of the cost-effectiveness of glaucoma treatments. OBJECTIVE: To develop and validate the preference-based Glaucoma Utility Instrument (Glau-U) and to ascertain the association between Glau-U utilities and severity of glaucoma and vision impairment. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was conducted in 2 stages at the Singapore National Eye Centre glaucoma clinics. Stage 1 focused on the identification and pretesting of the Glau-U attributes and was carried out between June 2009 and May 2016. Stage 2 involved the development and administration of the discrete choice experiment (DCE) survey and tasks and was conducted between May 7, 2018, and December 11, 2019. Stage 2 participants were English- or Mandarin-speaking Singaporean citizens or permanent residents of Chinese, Malay, or Indian ethnicity who were 40 years or older and had a clinical diagnosis of glaucoma in at least 1 eye. EXPOSURES: Glau-U comprised 6 quality-of-life attributes: activities of daily living, lighting and glare, movement, eye discomfort, other effects of glaucoma, and social and emotional effects. The descriptions or response options for these attributes were no difficulty or never, some difficulty or sometimes, or severe difficulty or often. MAIN OUTCOMES AND MEASURES: Utility weights for Glau-U were developed using a DCE questionnaire, which was interviewer administered to participants. Mixed logit regression determined utility weights for each health state. Glau-U utility weights across better- or worse-eye glaucoma and vision impairment severity were calculated using 1-way analysis of variance. Correlations between Glau-U utilities and better- or worse-eye visual fields and EuroQol 5-Dimension utilities were ascertained to assess convergent and divergent validity. RESULTS: Of the 304 participants (mean [SD] age, 68.3 [8.7] years; 182 men [59.9%]), 281 (92.4%) had no vision impairment in the better eye, 13 (4.3%) had mild impairment, and 10 (3.3%) had moderate to severe vision impairment. Mean (SD) Glau-U utilities decreased as better-eye glaucoma severity increased (none: 0.73 [0.21]; mild: 0.66 [0.21]; moderate: 0.66 [0.20]; severe: 0.60 [0.28]; and advanced or end-stage: 0.22 [0.38]; P < .001), representing reductions of 20.7% to 76.1% in quality-adjusted life-years compared with a health state that included preperimetric glaucoma. Mean (SD) Glau-U utilities also decreased as better-eye vision impairment worsened from 0.67 (0.23) for none to 0.58 (0.32) for mild to 0.46 (0.29) for moderate to severe vision impairment. Glau-U utilities demonstrated moderate correlations with better-eye (r = 0.34; P < .001) and worse-eye (r = 0.33; P < .001) mean deviation scores and low correlations with EuroQol 5-Dimension utilities (r = 0.22; P < .001), supporting convergent and divergent validity. CONCLUSIONS AND RELEVANCE: Use of Glau-U revealed large decrements in utility that were associated with late-stage glaucoma, suggesting that this new instrument may be useful for cost-effectiveness analyses of interventions and informing resource allocation policies for glaucoma and vision loss.
引用
- Fenwick EK, Ozdemir S, Man REK, et al. Development and Validation of a Preference-Based Glaucoma Utility Instrument Using Discrete Choice Experiment. JAMA Ophthalmol. 2021. PMID: 34165504. doi:10.1001/jamaophthalmol.2021.1874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。